This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Good morning ladies and gentlemen and welcome to the Kimball Electronics first quarter fiscal 2027 earnings conference call. My name is Ina and I will be the facilitator for today's call. All lines have been paced in lesson only mode to prevent any background noise. After the completion of the prepared remarks from the Kimball Electronics leadership team, there will be a question and answer period. To ask a question, simply press star then the number one on your telephone keypad. Today's call, November 5, 2026, is being recorded. A replay of the call will be available on the Investor Relations page of the Kimball Electronics website. At this time, I would like to turn the call over to Mr. Andrew Regrut, Vice President, Investor Relations, Strategic Development, and Treasurer. Mr. Regrut, you may begin.
Thank you, and good morning, everyone. Welcome to our first quarter conference call. With me here today is Rick Phillips, our Chief Executive Officer, and Jana Croom, Chief Financial Officer. We issued a press release yesterday afternoon with our results for the first quarter of fiscal 2027, ended September 30, 2026. To accompany today's call, presentation has been posted to the investor relations page on our company website. Before we get started, I'd like to remind you that we will be making forward-looking statements that involve risk and uncertainty, and are subject to our safe harbor provisions as stated in our press release and SEC filings, and that actual results can differ materially from the forward-looking statements. Our commentary today will be focused on adjusted non-GAAP results. Reconciliations of GAAP to non-GAAP amounts are available in our press release. This morning, Rick will start the call with a few opening comments. Jana will review the financial results for the quarter and guidance for fiscal 2027. and Rick will complete our prepared remarks before taking your questions. I'll now turn the call over to Rick.
Thank you, Andy. And good morning, everyone. I'm encouraged by our first quarter results and solid start to fiscal 2027. Sales increased both sequentially and year over year. Margins were healthy and cash conversion days were once again at a multi-year low. The top line benefited from organic sales growth and the contribution from Helbowit Polymer Technologies, our recent tuck-in acquisition in the medical CDMO. The organic growth was in line with expectations and driven by a high single-digit increase in medical sales. This growth aligns with our strategic focus to balance the portfolio across the verticals. Our excitement for the overall fit and growth opportunities of Helbowit are higher now than ever. With the backdrop of a strong balance sheet were investing in medical growth by integrating Helbowit, ramping operations in Indianapolis, leveraging our capabilities as a full service provider, and unlocking synergies across the global footprint. Fiscal 2027 marks an important milestone in our journey, and we are reiterating our guidance for the year with sales expected at the high end of the range, driven by continued strength in medical. Turning now to first quarter results Net sales for the total company were $391 million, a 5% increase on a sequential basis and up 7% when compared to Q1 of fiscal 2026. The year-over-year increase occurred in all verticals, with approximately 40% of total sales in North America and the remainder roughly split between Asia and Europe. Starting with medical. Sales in Q1 totaled $116 million, a 14% increase compared to the same period a year ago, and 29% of the total company. Broad-based organic growth drove a 9% increase in the quarter, with the strength across multiple product categories including drug delivery devices, respiratory care products, patient monitoring systems, single-use surgical instruments, and imaging systems. Industrial reported sales of $105 million, 5% higher than a year ago, and 27% of total company. Similar to medical, the organic growth accounted for a meaningful portion of the increase, over one-third of it, with strength in most of the product categories, including off-highway equipment, factory automation, public safety, and smart metering. Climate control was down again this quarter, driven by lower demand for HVAC systems, primarily in North America. We're seeing new and interesting opportunities in this vertical, which could leverage our expertise in electronics manufacturing and higher-level assemblies and drive future growth. Finally, sales in automotive were $171 million, a 4% increase year-over-year and 44% of the company. Steering drove the organic growth for us in this business, accounting for over 70% of automotive in Q1, with the ramp-up of a new program in Poland and early preparations for a transfer of production in China boosting the results. North America was sluggish once again this quarter, largely due to lower EV demand. Overall, I'm very pleased to see a return to growth and full-year sales trending to the top end of our guidance range. I'll now turn the call over to Jana for more details on the financials. Jana?
You're reading a preview of the KE Q1 2027 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing